USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant

12 Dec 2022 Evaluate

The US Food and Drug Administration (USFDA) has issued warning letter to Glenmark Pharmaceuticals for lapses at Goa plant. USFDA pointed out various lapses at the company's Bardez-based facility in Goa, which produces drug formulations.

As per the US Health regulator, the warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The USFDA inspected the manufacturing facility from May 12, 2022, to May 20, 2022.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2052.70 27.30 (1.35%)
02-Jan-2026 13:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.80
Dr. Reddys Lab 1248.35
Cipla 1503.60
Zydus Lifesciences 914.60
Lupin 2095.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×